Terapia génica: ¿es IL2RG oncogénico en el desarrollo de células T?

Karin Pike-Overzet1, Dick de Ridder, Floor Weerkamp

  • 1Department of Immunology, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.

Nature
|September 22, 2006
PubMed
Resumen

La terapia génica de cadena gamma del receptor de interleucina-2 (IL2RG) para la inmunodeficiencia grave combinada ligada al X (X-SCID) puede no ser directamente oncogénica. En cambio, la señalización restaurada permite el desarrollo de células T, lo que permite a los oncogenes como LMO2 promover la leucemia.

Videos de Conceptos Relacionados

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
22.1K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K